What is the effect of fructose consumption on markers of cardiometabolic disease, in comparison to glucose or sucrose?
Thank you for your support, which keeps us 100% independent. Click here to explore the perks of your membership.
Study under review: Effect of fructose instead of glucose or sucrose on cardiometabolic markers: a systematic review and meta-analysis of isoenergetic intervention trials
You are reading a free open article from our Examine Membership. Become an Examine Member to get full access and to stay on top of the latest research.
What was the question? How does fructose intake affect cardiometabolic disease risk markers compared to glucose or sucrose?
How was it answered? Researchers conducted a meta-analysis of randomized and nonrandomized clinical trials.
Who was studied? The trials included almost 2,000 participants, ages 13–62. Most studies involved people without a diagnosed disease, although some studies involved participants with glucose dysregulation or non-alcoholic fatty liver disease. Average BMI categories ranged from normal to obese.
What was the intervention? Participants followed diets containing a set amount of calories as fructose compared to similar diets containing the same amount of energy as glucose or sucrose in interventions lasting at least one week.
What's the main takeaway? There were no clear differences between the effects of fructose compared to the same amount of calories from glucose or sucrose, with two exceptions: researchers observed a small diastolic blood pressure drop when fructose was substituted for glucose, and a bump in apolipoprotein B levels when high-fructose corn syrup was substituted for sucrose.
Any caveats? Poor or unclear study quality and differences between the included studies warrant some caution when interpreting these results.
It’s often been argued that fructose is the primary driver of all cardiometabolic disease, but the evidence for this hypothesis is mixed at best.
Cardiometabolic diseases are a group of related metabolic disorders, including non-alcoholic fatty liver disease (NAFLD), type 2 diabetes mellitus (T2DM), obesity, cardiovascular disease (CVD), and metabolic syndrome. Each of these is linked to excess calorie intake, but preclinical studies, observational studies, and some clinical trials do suggest that fructose consumption might play a role in these conditions, even independently of calorie intake.
However, reviews looking at fructose in comparison to other common sugars like glucose, sucrose (a disaccharide of glucose and fructose, also called table sugar), and high fructose corn syrup (HFCS; a liquid sweetener typically containing 42–55% fructose) have provided mixed results. The main conclusions of these past studies are summarized in Figure 1. These previous meta-analyses do not converge on a clearly unified answer.
Isocaloric fructose may increase insulin resistance in the liver.
Metabolic syndrome components
Fructose consumption (not necessarily isocaloric) raised fasting blood sugar, blood pressure, and triglycerides.
Isocaloric fructose had no influence on body weight.
Isocaloric fructose had no influence on any blood lipid measurement.
Isocaloric fructose lowered after-meal blood glucose and insulin compared to sucrose or glucose.
Glycemic and cardiometabolic markers
Isocaloric fructose lowered fasting blood sugar, HbA1c, and bodyweight to small degrees.
How fructose compares to isocaloric amounts of other sugars in terms of cardiometabolic impact is an important question to address, since it takes calories out of the picture and determines how fructose compares toe-to-toe against other sugars. The present review provides the most up-to-date look at how the effects of fructose stack up against those of other sugars.
Dozens of studies and several meta-analyses have attempted to clarify the metabolic effects fructose might have relative to glucose. Although they are consistent with one another in some respects, areas of uncertainty remain.
The authors searched databases for human randomized and nonrandomized controlled trials that looked at interventions with a duration of more than one week in which researchers kept total calories the same while replacing fructose or high fructose corn syrup with sucrose or glucose. Included cardiometabolic outcomes were total cholesterol, low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C), circulating triglycerides (TGs), apolipoprotein A1 (ApoA1; a major protein component of HDL-C), apolipoprotein B (ApoB; a major protein component of LDL-C species), systolic blood pressure (SBP), diastolic blood pressure (DBP), fasting blood glucose, and bodyweight. This systematic review was preregistered and reported in accordance with PRISMA guidelines.
The systematic review ultimately yielded 25 trials that looked at the effect of replacing fructose or HFCS with the same number of calories of sucrose or glucose over the course of one week or longer in humans and reported data for accompanying physiological effects. A total of 1,744 participants (47% female) ages 13–62 were included in the analysis. Eighteen studies compared fructose with glucose, 5 compared HFCS with glucose, 10 compared fructose with sucrose, and 5 compared HFCS with sucrose. The study duration ranged from 1–12 weeks (median of 3 weeks). The fructose dose ranged from 33–250 grams, representing 6–48% of the total daily calories provided by the diets. Nine of the 25 studies recruited participants with obesity or type 2 diabetes. Seven studies were classified as having low risk of bias, 6 as having high risk of bias, and 12 as having uncertain risk of bias.
The researchers estimated the percentage of the total variation due to heterogeneity, rather than to chance. Risk of publication bias and quality of evidence were also evaluated. Seven studies were supported exclusively by public institutions, while the others were entirely or partially supported by commercial funds. In fact, this meta-analysis was also supported by funds from a candy manufacturing and research organization in Italy.
This systematic review and meta-analysis pooled data from 25 controlled trials to determine the effects of fructose on fasting glucose, blood lipids, blood pressure and weight, compared to glucose.
When glucose was replaced with fructose, no significant differences were found for fasting blood glucose, bodyweight, systolic blood pressure, ApoA1, ApoB, TGs, HDL-C, or LDL-C. The one significant effect found was diastolic blood pressure (the bottom number in a blood pressure reading, the blood pressure between heart beats) decreased by 2.44 mmHg when glucose was replaced by fructose. This effect lost statistical significance when non-randomized trials were removed from the analysis, when studies with highest risk of bias were removed, and also when either of the two studies with the greatest effect sizes were removed.
Replacing HFCS with glucose did not change any cardiometabolic parameters in any meaningful way, nor did replacing fructose with sucrose.
Replacing HFCS with sucrose was not associated with a meaningful effect on total cholesterol, LDL-C, HDL-C, or TGs, but was associated with a significant decrease in apoB by a WMD of 11.29 mg/dL. For reference, physicians commonly recommend that ApoB should be lower than 130 mg/dL to prevent cardiovascular disease, and the participants from the sole study that reported on apoB changes had baseline levels of around 85–100 mg/dL. Little confidence can be placed on this latter result because it was based on a single study and it contradicts the null effects seen when replacing pure fructose with sucrose.
As an aside, note that the numbers pulled from the above study that reported on apoB don’t agree with what the authors of the study under review reported in their meta-analysis. There are also some other discrepancies in their references.
Other than these findings, there were no other differences found. The only differences that were found are summarized in Figure 2.
This systematic review and meta-analysis shows that, by and large, there does not appear to be much difference in the metabolic effect of fructose as compared to glucose. Replacing glucose with fructose might lower diastolic blood pressure by a small amount, and replacing high fructose corn syrup with sucrose might decrease apolipoprotein B, though confidence in these results is low.
If you are a long-time Study Deep Dives reader, these results probably don’t surprise you. Study Deep Dives has covered recent systematic reviews about the differential effects, or lack thereof, of types of sugar for some time. Check out two previous Study Deep Dives deep dives on fructose, Sugar Wars, Episode 4: A New Hope for Fructose, on the acute and chronic glycemic effect of fructose, and Sugar Wars, Episode 2: Fructose Strikes Back, on fructose and blood lipid levels for a more in-depth take.
Previous human research points to the lack of a consistent effect of fructose above and beyond that of other sugars when it comes to bodyweight and other cardiometabolic measures, but results from previous meta-analyses still differ. In this study, the authors add authority to their analysis by paying attention to details like excluding non-isocaloric comparisons in the first place, employing rigorous sensitivity and heterogeneity analyses, and adjusting for effect-modifiers. That said, it’s unclear why there are discrepancies between data reported in this meta-analysis and some of the data from the original studies. Overall, this meta-analysis appears to be one of the most thorough investigations on the subject, but review confidence is reduced because some inconsistencies in the findings for apoB and FBG cannot be reconciled.
Even if these results are mostly in-line with other research, they lie in contrast to the conclusions of some outspoken clinician-researchers, such as Dr. Robert Lustig’s “unifying hypothesis of metabolic syndrome,” which proposes that fructose may be uniquely metabolically damaging, particularly to the liver. Though this meta-analysis does not specifically focus on the liver, it suggests that commonly-measured markers of cardiovascular and metabolic health respond similarly to fructose and glucose, challenging the importance of distinguishing between these two sugars.
Some look to fructose’s effect of elevating uric acid (not measured in this meta-analysis) as the primary driver of its adverse metabolic effects. This theory may explain why fructose could indirectly lead to gout, as evidenced in observational studies, and hyperuricemia, as seen in clinical trials. However, if fructose was the primary driver of NAFLD and other cardiometabolic diseases, then this would be indicated by increased markers of hepatic de novo lipogenesis, LDL-C, ApoB, and TGs, which are only inconsistently suggested by the evidence. To cast further doubt on this theory, one isotopic tracer label study showed that 29–54% of ingested fructose is converted to glucose and 28% is converted to lactate, whereas less than 1% of dietary fructose is converted to plasma triglycerides.
The fact that so many previous meta-analyses have come up with slightly divergent results can be explained by a few factors. The first explanation is “statistical noise”—even if there’s no effect, results will be expected to come up with positive results on occasion (1 out of 20 times, assuming standard statistical analyses). Since different meta-analyses often include different sets of trials, the results that show up by chance can differ between studies.
Another explanation involves the possibility of substandard statistical analyses. The present meta-analysis looked at a number of sources of bias, including heterogeneity among studies, effect modification of certain variables, publication bias, and presence of individual studies that skew the agglomerated results. Once these were accounted for, all of the statistically significant results were washed out. Some of the other research studies found similarly bias-confounded results, while others only found significant results when looking at studies in which calories were added on top of usual intake. These explanations also account for the reason why the same team’s previous meta-analysis suggested a modest effect on FBG, which was not found in this analysis: having more data allowed them to attribute the effect to heterogeneity between studies.
Another key point is that many of these studies used very large fructose exposures. The fact that these excessive doses produced few, if any, significantly different results means that typical intakes are even less likely to produce differences over the time scales investigated. A median of 9% of an American’s calorie intake consists of fructose, equating to about 192 kilocalories or 48 grams of fructose per day. To put this into perspective, 29 of the 35 comparison arms used to determine the results of this meta-analysis included doses of fructose higher than the median intake, and 8 of the comparison arms were in excess of 99% of American adult’s fructose intakes. These supraphysiological doses are used often in preclinical animal studies, but they can’t provide a realistic effect of a more relevant dose of fructose.
Fructose and glucose are calorically the same, gram for gram. In terms of weight gain (positive energy balance) and weight loss (negative energy balance), there is no clear a priori reason to think that fructose would drive weight gain differently than other sugars. Even when it comes to fullness and hunger hormones, fructose appears to be at least as filling as glucose, if not more so 30 minutes after ingestion.
Even if the observed differences between glucose and fructose metabolism in previous meta-analyses are real and not due to chance or confounding, you would have to consume an unusually large amount of sugar to feel those fructose-specific effects. By then, however, you would be consuming a damaging amount of highly refined carbohydrate anyway. For example, imagine drinking two different extra-large soft drinks, one sweetened with fructose and the other sweetened with the same amount of glucose. It will be drinking that much soda in the first place that causes a calorie surplus and harmful cardiometabolic effects, not a unique feature of the type of sugar being consumed. With many of the measured cardiometabolic markers being responsive to energy balance, and considering the mere fact that a molecule of fructose does not contribute any more to weight status than a molecule of glucose, it’s no surprise that the effect of fructose on cardiovascular and metabolic health parameters does not stand out from other refined carbohydrates.
This meta-analysis confirms what other high quality reviews have already suggested: the adverse metabolic effect of fructose is comparable to that of glucose.
This meta-analysis found that fructose consumption is no better or worse, cardiometabolically, than consuming glucose or other fructose-glucose combinations like sucrose and high fructose corn syrup. The metabolic effects seen in previous meta-analyses were not observed in this latest meta-analysis (e.g. increased TGs at high fructose doses, decreased SBP, increased weight) may have more to do with statistical noise or with other variables not fully accounted for.
The negative metabolic effects of excess fructose consumption are most likely tied to excess energy consumption and the relative absence of fiber, phytochemicals, and essential micronutrients in highly refined carbohydrates, rather than any unique effect of fructose itself.
You are reading a free open article from Examine Membership. Become a subscriber to get full access and to stay on top of the latest research.
Other Articles in Issue #75 (January 2021)
Safety Spotlight: Women and creatine
The effects of creatine are quite well studied, but its sex-specific safety profile hasn't been. Besides some non-serious side effects, creatine seems safe for women, but more work needs to understand creatine's effects during pregnancy.
The effects of increased protein intake on overall energy intake in older adults
Boosting protein intake may help stave off the loss of muscle strength and function that can come with age. But does increasing protein affect energy intake in older adults as well? We cover a recent meta-analysis that explored this question.
Deep Dive: Supplementing for senior strength and size in the context of sarcopenia
This systematic review and meta-analysis explored what supplements can stave off the loss of muscle function that comes with aging. However, the way it categorized the studies it used, along with the overall low quality of those studies, makes its conclusions seem a bit... weak.
Interview: Cyriac Abby Philips, MBBS, MD, DM (Hepatology)
In this interview, we pick Dr. Philips' brain about the basics of Ayurveda, its safety, and the story behind a recently retracted paper he was involved with detailing a case of acute liver failure and death in a patient who was taking supplements.
Deep Dive: Comparing the efficacy of diet, exercise, and lifestyle modifications for controlling childhood obesity
This meta-analysis looked at what lifestyle interventions work best for children with overweight and obesity, and how much of a role parental involvement played.
Deep Dive: Do Low-Carb Diets Stoke the Metabolic Fire?
This meta-analysis concluded that longer-term low-carb dieters feel the metabolic burn, but some methodological concerns may douse this flame a bit.
Deep Dive: Evaluating the relationship between training status and optimal protein intake
According to this recent meta-analysis, whether or not more protein is better for lean body mass may come down to resistance training status.
- Metabolic effects of fructose. Curr Opin Clin Nutr Metab Care. (2006) Kim-Anne Lê, Luc Tappy.
- Potential role of sugar (fructose) in the epidemic of hypertension, obesity and the metabolic syndrome, diabetes, kidney disease, and cardiovascular disease. Am J Clin Nutr. (2007) Richard J Johnson, et al.
- Consuming fructose-sweetened, not glucose-sweetened, beverages increases visceral adiposity and lipids and decreases insulin sensitivity in overweight/obese humans. J Clin Invest. (2009) Kimber L Stanhope, et al.
- Effect of fructose consumption on insulin sensitivity in nondiabetic subjects: a systematic review and meta-analysis of diet-intervention trials. Am J Clin Nutr. (2016) Ter Horst KW, et al.
- Association of fructose consumption and components of metabolic syndrome in human studies: a systematic review and meta-analysis. Nutrition. (2014) Roya Kelishadi, Marjan Mansourian, Motahar Heidari-Beni.
- Effect of fructose on body weight in controlled feeding trials: a systematic review and meta-analysis. Ann Intern Med. (2012) Sievenpiper JL, et al.
- Effect of Fructose on Established Lipid Targets: A Systematic Review and Meta-Analysis of Controlled Feeding Trials. J Am Heart Assoc. (2015) Laura Chiavaroli, et al.
- Fructose replacement of glucose or sucrose in food or beverages lowers postprandial glucose and insulin without raising triglycerides: a systematic review and meta-analysis. Am J Clin Nutr. (2017) Rebecca A Evans, et al.
- Chronic fructose substitution for glucose or sucrose in food or beverages has little effect on fasting blood glucose, insulin, or triglycerides: a systematic review and meta-analysis. Am J Clin Nutr. (2017) Evans RA, et al.
- The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ. (2009) Liberati A, et al.
- The effect of normally consumed amounts of sucrose or high fructose corn syrup on lipid profiles, body composition and related parameters in overweight/obese subjects. Nutrients. (2014) Joshua Lowndes, et al.
- Toward a Unifying Hypothesis of Metabolic Syndrome. Pediatrics. (2012) Andrew A Bremer, Michele Mietus-Snyder, Robert H Lustig.
- Fructose and sugar: A major mediator of non-alcoholic fatty liver disease. J Hepatol. (2018) Thomas Jensen, et al.
- Challenging the Fructose Hypothesis: New Perspectives on Fructose Consumption and Metabolism. Adv Nutr. (2013) John S White.
- Dietary sugars and cardiometabolic risk factors: a network meta-analysis on isocaloric substitution interventions. Am J Clin Nutr. (2020) Lukas Schwingshackl, et al.
- Consumption of sugar-sweetened beverages and serum uric acid concentrations: a systematic review and meta-analysis. J Hum Nutr Diet. (2020) S Ebrahimpour-Koujan, et al.
- Important food sources of fructose-containing sugars and incident gout: a systematic review and meta-analysis of prospective cohort studies. BMJ Open. (2019) Sabrina Ayoub-Charette, et al.
- Consumption of sugar sweetened beverages and dietary fructose in relation to risk of gout and hyperuricemia: a systematic review and meta-analysis. Crit Rev Food Sci Nutr. (2020) Soraiya Ebrahimpour-Koujan, et al.
- Fructose vs. glucose and metabolism: do the metabolic differences matter?. Curr Opin Lipidol. (2014) John L Sievenpiper, et al.
- Fructose Metabolism in Humans - What Isotopic Tracer Studies Tell Us. Nutr Metab (Lond). (2012) Sam Z Sun, Mark W Empie.
- Effects of free sugars on blood pressure and lipids: a systematic review and meta-analysis of nutritional isoenergetic intervention trials. Am J Clin Nutr. (2017) Elena Fattore, et al.
- Fructose and non-fructose sugar intakes in the US population and their associations with indicators of metabolic syndrome. Food Chem Toxicol. (2011) Sam Z Sun, et al.
- Is fructose a story of mice but not men?. J Am Diet Assoc. (2011) John L Sievenpiper, et al.
- Fructose and satiety. J Nutr. (2009) Timothy H Moran.
- Effects of glucose and fructose solutions on food intake and gastric emptying in nonobese women. Am J Physiol. (1994) J L Guss, H R Kissileff, F X Pi-Sunyer.
- Comparative effects of fructose, aspartame, glucose, and water preloads on calorie and macronutrient intake. Am J Clin Nutr. (1990) J Rodin.
- Fructose consumption and consequences for glycation, plasma triacylglycerol, and body weight: meta-analyses and meta-regression models of intervention studies. Am J Clin Nutr. (2008) Livesey G, Taylor R.